A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery

International Journal of Pharmaceutics

Volumn 458, Issue 1, 2013, Pages 110-117

  Ye, Yajing ^a   Sun, Yi ^a   Zhao, Hongli ^a   Lan, Minbo ^a   Gao, Feng ^a   Song, Chao ^a   Lou, Kaiyan ^a   Li, Hao ^a   Wang, Wei ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

beta; cyclodextrin derivatives; Brain targeting; Lactoferrin; Nano drug delivery system; Transferrin

Indexed keywords

BETA CYCLODEXTRIN; FLUORESCENT DYE; IR 775 CHLORIDE; LACTOFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PC12 CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

BRAIN-TARGETING; LACTOFERRIN; NANO-DRUG DELIVERY SYSTEM; TRANSFERRIN; Β-CYCLODEXTRIN DERIVATIVES;

ANIMALS; BETA-CYCLODEXTRINS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LACTOFERRIN; MICE; NANOPARTICLES; PARTICLE SIZE; PC12 CELLS; POLYETHYLENE GLYCOLS; RATS; TISSUE DISTRIBUTION;

EID: 84888376188     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.10.005     Document Type: Article

References (31)

1. M. Adenot, P. Merida, and R. Lahana Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents, 2. Cationic peptide vectors for brain delivery Chemotherapy 53 2007 73 76 (Pubitemid 46143858)
2. S. Bhaskar, F. Tian, T. Stoeger, W. Kreyling, V. Grazu, P. Borm, G. Estrada, V. Ntziachristos, and D. Razansky Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging Part. Fibre Toxicol. 7 2010 3
3. P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, and C. Rossi Solid lipid nanoparticles for targeted brain drug delivery Adv. Drug Deliv. Rev. 59 2007 454 477 (Pubitemid 47259226)
4. R.J. Boado, Y. Zhang, and W.M. Pardridge Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier Biotechnol. Bioeng. 96 2007 381 391 (Pubitemid 46232272)
5. P. Calvo, B. Gouritin, H. Chacun, D. Desmaële, J. D'Angelo, and J.P. Noel Long-circulating PEG5000ylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery Pharm. Res. 18 2001 1157 1166 (Pubitemid 32900402)
6. Y. Chen, and L.H. Liu Modern methods for delivery of drugs across the blood-brain barrier Adv. Drug Deliv. Rev. 64 2012 640 665
7. M.T. da Cruz, S. Simoes, and M.C. de Lima Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons Exp. Neurol. 187 2004 65 75 (Pubitemid 38470013)
8. F. Denizot, and R. Lang Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89 1986 271
9. S. Deshayes, M.C. Morris, G. Divita, and F. Heitz Cell-penetrating peptides: tools for intracellular delivery of therapeutics Cell. Mol. Life Sci. 62 2005 1839 1849 (Pubitemid 41188523)
10. G.L. Ellmann Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
11. M.F. Fromm P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs Int. J. Clin. Pharmacol. Ther. 38 2000 69 74 (Pubitemid 30077981)
12. P.J. Gaillard, A. Brink, and A.G. de Boer Diphtheria toxin receptor-targeted brain drug delivery Int. Congr. Ser. 1277 2005 185 198 (Pubitemid 43693328)
13. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 2005 274 292 (Pubitemid 40910731)
14. H.J. Vogel Lactoferrin, a bird's eye view Biochem. Cell Biol. 90 2012 233 244
15. K. Hu, J. Li, Y. Shen, W. Lu, X. Gao, Q. Zhang, and X. Jiang Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations J. Control. Release 134 2009 55 61
16. K. Hu, Y. Shi, W. Jiang, J. Han, S. Huang, and X. Jiang Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease Int. J. Pharm. 415 2011 273 283
17. B. Ji, J. Maeda, M. Higuchi, K. Inoue, H. Akita, H. Harashima, and T. Suhara Pharmacokinetics and brain uptake of lactoferrin in rats Life Sci. 78 2006 851 855 (Pubitemid 43082309)
18. A.V. Kabanov, E.V. Batrakova, and D.W. Miller Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier Adv. Drug Deliv. Rev. 55 2003 151 164 (Pubitemid 36078456)
19. L. Liu, and S. Zhu A study on the supramolecular structure of inclusion complex of β-cyclodextrin with prazosin hydrochloride Carbohydr. Lett. 68 2007 472 476 (Pubitemid 46365946)
20. H.M.C. Marques, J. Hadgraft, and I.W. Kellaway Studies of cyclodextrin inclusion complexes I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC Int. J. Pharm. 63 1990 259 266
21. V. Monnaert, S. Tilloy, H. Bricout, L. Fenart, R. Cecchelli, and E. Monflier Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier J. Pharmacol. Exp. Ther. 310 2004 745 751 (Pubitemid 38988921)
22. E.A. Nance, G.F. Woodworth, K.A. Sailor, T.-Y. Shih, Q. Xu, G. Swaminathan, D. Xiang, C. Eberhart, and J. Hanes A dense poly (ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue Sci. Transl. Med. 4 2012 149ra119
23. J.C. Olivier, R. Huertas, H.J. Lee, F. Calon, and W.M. Pardridge Synthesis of PEG5000ylated immunonanoparticles Pharm. Res. 19 2002 1137 1143
24. J. Qin, D. Chen, H. Hu, Q. Cui, M. Qiao, and B. Chen Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain Chem. Pharm. Bull. 55 2007 1192 1197 (Pubitemid 47344972)
25. A. Susana, González-Chávez, Sigifredo Arévalo- Gallegos, and Quintín Rascón-Cruz Lactoferrin: structure, function and applications Int. J. Antimicrob. Agents 33 2009 301.e1 301.e8
26. K. Ulbrich, T. Hekmatara, E. Herbert, and J. Kreuter Transferrin- and transferring-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71 2009 251 256
27. I. van Rooy, E. Mastrobattista, G. Storm, W.E. Hennink, and R.M. Schiffelers Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J. Control. Release 150 2011 30 36
28. N. Vykhodtseva, N. McDannold, and K. Hynynen Progress and problems in the application of focused ultrasound for blood-brain barrier disruption Ultrasonics 48 2008 279 296
29. Y. Zhang, R.J. Boado, and W.M. Pardridge Marked enhancement in gene expression by targeting the human insulin receptor J. Gene Med. 5 2003 157 163 (Pubitemid 40309692)
30. Y. Zhang, F. Calon, C. Zhu, R.J. Boado, and W.M. Pardridge Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism Hum. Gene Ther. 14 2003 1 12 (Pubitemid 36126683)
31. Y. Zhang, F. Schlachetzki, Y.F. Zhang, R.J. Boado, and W.M. Pardridge Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promote Hum. Gene Ther. 15 2004 339 350 (Pubitemid 38469776)